The Advisory Committee on Immunization Practices released its updated annual immunization schedule for 2024 that includes new sections on respiratory syncytial virus (RSV), and the mpox (monkeypox) and...
The CDC updated its guidance due to the United States seeing fewer hospitalizations associated with COVID-19 and because there are numerous tools to combat influenza, COVID-19, and respiratory syncytial...
This COVID-19 roundup includes coverage of the FDA’s guidance for the correct Moderna vaccine dosage for pediatric patients, COVID-19 outcomes for patients with hypertension and diabetes, and the risk of...
Earlier this year, the FDA approved the same vaccine for the prevention of lower respiratory tract disease caused by RSV in individuals 60 years of age and older.
Following three clinical trials, the FDA has approved a new preventive treatment for neonates, infants, and toddlers that prevents respiratory syncytial virus (RSV) in those age populations.
This FDA Roundup includes an at-a-glance look at the latest FDA drug approvals in April and May, including treatment for menopausal hot flashes, Clostridioides difficile infection, suspected opioid...
